PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2,...
Hence then, the article about taiho oncology and cullinan therapeutics announce pivotal rezilient1 phase 1 2 data published in the journal of clinical oncology was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology )
Also on site :
- U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
- Goldfish Is Offering Fans Free Crackers for Tax Day—Here’s How To Claim Yours
- I had a sexual awakening at 43 – and lost my husband because of it